Evidence mapPaperPMID 41899603Full record

ReviewCancers2026

Crosstalk Between

Yuqing Ren, Di Tang, Xiaofan Ding, Mian He

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuqing RenFaculty of Health Sciences, University of Macau, Macau SAR 999078, China.
Di TangDepartment of General Surgery, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.
Xiaofan DingFaculty of Health Sciences, University of Macau, Macau SAR 999078, China.ORCID 0000-0003-2565-7757
Mian HeDepartment of General Surgery, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.

Funding

Macau Science and Technology Development Fund 0032/2022/A1National Nature Science Foundation of China 82203432Shenzhen Science and Technology Innovation Program JCYJ20220530144800002
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, arising from profound metabolic reprogramming and widespread epigenetic dysregulation. However, the role of epigenetic aberrations in modulating metabolic reprogramming and the interplay between

Indexed as

Cis-regulatory elementshepatocellular carcinomametabolic reprogramming

Identifiers

PMID41899603
PMCPMC13025584

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.